Pharmacology · 2012 · 27 citations · 50 references
MedicineNeurosciencePharmacologyNeuropharmacologyPain MedicinePharmacodynamicsAnalgesiaAnalgesic PharmacologyCannabinoid PharmacologyOpioid AnalgesicsOpioid PharmacologyPain NeurobiologyAnalgesic Drug MechanismsAnalgesic EffectsCannabinoid AnalgesicsCannabinoid AntagonistsCentral Analgesic MechanismsEndogenous Opioid SignalingEndogenous OpioidsOpioid Antagonists
BACKGROUND/AIMS: In this study we analyzed the mechanisms underlying celecoxib-induced analgesia in a model of inflammatory pain in rats, using the intracerebroventricular (i.c.v.) administration of selective opioid and cannabinoid antagonists. METHODS AND RESULTS: Analgesic effects of celecoxib were prevented by selective μ-(β-funaltrexamine) and δ-(naltrindole), but not κ-(nor-binaltorphimine) opioid antagonists, given i.c.v. 30 min before celecoxib. Similar pretreatment with AM 251, but not SR 144528, cannabinoid CB(1) and CB(2) receptor antagonists, respectively, prevented celecoxib-induced analgesia. The fatty acid amide hydrolase inhibitor, URB 597, also prevented celecoxib-induced analgesia. CONCLUSIONS: Our data provided further evidence for the involvement of endogenous opioids and revealed a new cannabinoid component of the mechanism(s) underlying celecoxib-induced analgesia.
50
Ethical guidelines for investigations of experimental pain in conscious animals
M. Zimmermann · Pain · 1983 · 7.8K citations
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Benjamin F. Cravatt, Dan K. Giang, Stephen P. Mayfield et al. · Nature · 1996 · 2.1K citations
Thomas D. Penning, John J. Talley, Stephen R. Bertenshaw et al. · Journal of Medicinal Chemistry · 1997 · 2K citations · Full text